• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lifshitz Law PLLC Announces Investigations of BG, KDNY, QUOT, and DICE

    6/24/23 8:11:00 PM ET
    $BG
    $DICE
    $KDNY
    $QUOT
    Packaged Foods
    Consumer Staples
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BG alert in real time by email

    NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) --

    Bunge Limited (NYSE:BG)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of BG and Viterra Limited. Under the terms of the agreement, Viterra Limited shareholders will receive approximately 65.6 million shares of BG common stock and $2.0 billion in cash. In addition, BG will assume $9.8 billion of Viterra Limited debt and BG plans to repurchase $2.0 billion of BG common stock.

    If you are a BG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

    Chinook Therapeutics, Inc. (NASDAQ:KDNY)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of KDNY to Novartis AG for $40.00 per share in cash, plus a CVR of up to $4.00 per share payable upon the achievement of certain future regulatory milestones with respect to its lead product candidate, atrasentan.

    If you are a KDNY investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

    Quotient Technology, Inc. (NYSE:QUOT)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of QUOT to Neptune Retail Solutions for $4.00 per share in cash.

    If you are a QUOT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

    DICE Therapeutics, Inc. (NASDAQ:DICE)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of DICE to Eli Lilly & Co. for $48.00 per share in cash.

    If you are a DICE investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

    ATTORNEY ADVERTISING.© 2023 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

    Contact:

    Joshua M. Lifshitz, Esq.

    Lifshitz Law PLLC

    Phone: 516-493-9780

    Facsimile: 516-280-7376

    Email: info@lifshitzlaw.com



    Get the next $BG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BG
    $DICE
    $KDNY
    $QUOT

    CompanyDatePrice TargetRatingAnalyst
    Bunge Limited
    $BG
    12/16/2025$120.00Equal-Weight → Overweight
    Morgan Stanley
    Bunge Limited
    $BG
    11/6/2025$120.00Equal Weight → Overweight
    Barclays
    Bunge Limited
    $BG
    8/20/2025$95.00Overweight
    Analyst
    Bunge Limited
    $BG
    1/21/2025$115.00 → $95.00Overweight → Equal Weight
    Barclays
    Bunge Limited
    $BG
    8/1/2024$125.00 → $114.00Buy → Neutral
    Citigroup
    Bunge Limited
    $BG
    2/9/2024$122.00 → $105.00Hold → Buy
    HSBC Securities
    Bunge Limited
    $BG
    2/1/2024$108.00Buy
    Citigroup
    Bunge Limited
    $BG
    1/10/2024Outperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $BG
    $DICE
    $KDNY
    $QUOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Neppl John W was granted 20,113 shares and covered exercise/tax liability with 9,161 shares, increasing direct ownership by 8% to 148,958 units (SEC Form 4)

    4 - Bunge Global SA (0001996862) (Issuer)

    3/17/26 6:42:34 PM ET
    $BG
    Packaged Foods
    Consumer Staples

    Chief Legal Officer Podwika Joseph covered exercise/tax liability with 5,074 shares and was granted 11,429 shares, increasing direct ownership by 7% to 92,002 units (SEC Form 4)

    4 - Bunge Global SA (0001996862) (Issuer)

    3/17/26 6:42:39 PM ET
    $BG
    Packaged Foods
    Consumer Staples

    EVP and CSO Dimopoulos Christos was granted 14,178 shares and returned $111,559 worth of shares to the company (888 units at $125.63), increasing direct ownership by 13% to 118,205 units (SEC Form 4)

    4 - Bunge Global SA (0001996862) (Issuer)

    3/17/26 6:42:28 PM ET
    $BG
    Packaged Foods
    Consumer Staples

    $BG
    $DICE
    $KDNY
    $QUOT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mahoney Christopher bought $408,650 worth of shares (5,000 units at $81.73), increasing direct ownership by 231% to 7,164 units (SEC Form 4)

    4 - Bunge Global SA (0001996862) (Issuer)

    8/20/25 6:37:27 PM ET
    $BG
    Packaged Foods
    Consumer Staples

    $BG
    $DICE
    $KDNY
    $QUOT
    SEC Filings

    View All

    Bunge Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Bunge Global SA (0001996862) (Filer)

    4/2/26 4:06:30 PM ET
    $BG
    Packaged Foods
    Consumer Staples

    Bunge Limited filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Bunge Global SA (0001996862) (Filer)

    4/1/26 4:03:40 PM ET
    $BG
    Packaged Foods
    Consumer Staples

    Amendment: SEC Form SCHEDULE 13G/A filed by Bunge Limited

    SCHEDULE 13G/A - Bunge Global SA (0001996862) (Subject)

    3/26/26 4:41:10 PM ET
    $BG
    Packaged Foods
    Consumer Staples

    $BG
    $DICE
    $KDNY
    $QUOT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bunge Schedules First Quarter 2026 Earnings Release and Conference Call

    Bunge Global SA (NYSE:BG) will announce its results for the quarter ended March 31, 2026, on Wednesday, April 29, 2026, prior to the market opening. Company management will also host a conference call at 7 a.m. Central Time to discuss the results. A slide presentation to accompany the discussion will be posted at www.bunge.com. To access the webcast, go to "Events & Presentations" under "News & Events" in the "Investor Center" section of the company's website. Select "Q1 2026 Bunge Global SA Conference Call" and follow the prompts. Please go to the website at least 15 minutes prior to the call to register and download any necessary audio software. To listen to the call, please dial 1-84

    3/31/26 7:00:00 AM ET
    $BG
    Packaged Foods
    Consumer Staples

    Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Bunge Global, SA (NYSE: BG)

    NOTE TO EDITORS: The Following Is an Investment Opinion Issued by Spruce Point Capital Management Provides Analysis That Suggests Bunge Is a Non-Economic Agribusiness Roll-Up That Has Generated a Capital Deficit of $1.6 Billion After Capex, Business Investment and Asset-Shuffling, Making Its $4.7 and $3.9 Billion of Dividends and Share Repurchases Effectively Debt Financed Believes That Bunge Is Suffering Core Challenges In Its Oilseeds Business as Its Food Products and Alcoholic Beverage Clients Grapple With Changing Consumer Demand and The Effects of GLP-1 Weight Loss Drugs Presents Evidence That Bunge, Pro Forma For the Viterra Acquisition, Wildly Missed 2025 EBITDA Projections By

    3/25/26 9:04:00 AM ET
    $BG
    Packaged Foods
    Consumer Staples

    Bunge Recognized as One of the 2026 World's Most Ethical Companies®

    Ethisphere recognition honors organizations committed to business integrity through ethics, compliance, and governance programs Bunge (NYSE:BG) has been named as one of the 2026 World's Most Ethical Companies® by Ethisphere, a global leader in defining and advancing the standards of ethical business practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318370206/en/Bunge Recognized as One of the 2026 World's Most Ethical Companies® "Being named a World's Most Ethical Companies honoree reflects the work our teams around the world have done to strengthen our ethics and compliance culture across Bunge, in a year of immense

    3/18/26 2:00:00 PM ET
    $BG
    Packaged Foods
    Consumer Staples

    $BG
    $DICE
    $KDNY
    $QUOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bunge upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Bunge from Equal-Weight to Overweight and set a new price target of $120.00

    12/16/25 8:22:53 AM ET
    $BG
    Packaged Foods
    Consumer Staples

    Bunge upgraded by Barclays with a new price target

    Barclays upgraded Bunge from Equal Weight to Overweight and set a new price target of $120.00

    11/6/25 7:38:39 AM ET
    $BG
    Packaged Foods
    Consumer Staples

    Analyst resumed coverage on Bunge with a new price target

    Analyst resumed coverage of Bunge with a rating of Overweight and set a new price target of $95.00

    8/20/25 8:33:18 AM ET
    $BG
    Packaged Foods
    Consumer Staples

    $BG
    $DICE
    $KDNY
    $QUOT
    Leadership Updates

    Live Leadership Updates

    View All

    Bunge Announces Approval of Quarterly Dividends and Changes to Board of Directors by Shareholders at 2025 Annual General Meeting

    Shareholders of Bunge Global SA (NYSE:BG) approved a cash dividend in the amount of $2.80 per share, payable in four equal installments of $0.70, at the company's 2025 Annual General Meeting held in Switzerland today ("AGM"). The dividends will be paid as indicated below: Bunge Quarter, Fiscal Year Payment Date Record Date Amount 2nd Quarter, Fiscal Year 2025 June 2, 2025 May 19, 2025 $0.70 3rd Quarter, Fiscal Year 2025 September 2, 2025 August 19, 2025 $0.70 4th Quarter, Fiscal Year 2025 December 1, 2025 November 17, 2025 $0.70 1st Quarter, Fiscal Year 2026 March 3, 2026 February 17, 2026 $0.70 Shareholders also approv

    5/15/25 5:00:00 PM ET
    $BG
    Packaged Foods
    Consumer Staples

    Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates

    SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the first quarter ended March 31, 2023 and provided corporate updates. "During the first quarter of 2023, we continued to advance our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases. We recently completed full enrollment of the phase 3 ALIGN clinical trial, are on track to initiate the phase 3 BION-1301 IgAN clinical trial mid-year and expect to report topline ALIGN results in the fourth quarter of thi

    5/9/23 4:00:00 PM ET
    $KDNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors

    SEATTLE, April 13, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Robert W. Azelby to its Board of Directors. Mr. Azelby brings more than 20 years of executive leadership and commercial experience in the biopharmaceutical industry to Chinook. "We are thrilled to welcome Bob to Chinook's board of directors as we advance our pipeline through key milestones in 2023 and beyond," said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. "Bob brings significant industry experience in bu

    4/13/23 8:00:00 AM ET
    $KDNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BG
    $DICE
    $KDNY
    $QUOT
    Financials

    Live finance-specific insights

    View All

    Bunge Schedules First Quarter 2026 Earnings Release and Conference Call

    Bunge Global SA (NYSE:BG) will announce its results for the quarter ended March 31, 2026, on Wednesday, April 29, 2026, prior to the market opening. Company management will also host a conference call at 7 a.m. Central Time to discuss the results. A slide presentation to accompany the discussion will be posted at www.bunge.com. To access the webcast, go to "Events & Presentations" under "News & Events" in the "Investor Center" section of the company's website. Select "Q1 2026 Bunge Global SA Conference Call" and follow the prompts. Please go to the website at least 15 minutes prior to the call to register and download any necessary audio software. To listen to the call, please dial 1-84

    3/31/26 7:00:00 AM ET
    $BG
    Packaged Foods
    Consumer Staples

    Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Bunge Global, SA (NYSE: BG)

    NOTE TO EDITORS: The Following Is an Investment Opinion Issued by Spruce Point Capital Management Provides Analysis That Suggests Bunge Is a Non-Economic Agribusiness Roll-Up That Has Generated a Capital Deficit of $1.6 Billion After Capex, Business Investment and Asset-Shuffling, Making Its $4.7 and $3.9 Billion of Dividends and Share Repurchases Effectively Debt Financed Believes That Bunge Is Suffering Core Challenges In Its Oilseeds Business as Its Food Products and Alcoholic Beverage Clients Grapple With Changing Consumer Demand and The Effects of GLP-1 Weight Loss Drugs Presents Evidence That Bunge, Pro Forma For the Viterra Acquisition, Wildly Missed 2025 EBITDA Projections By

    3/25/26 9:04:00 AM ET
    $BG
    Packaged Foods
    Consumer Staples

    Bunge Outlines Strategic Growth and Value Creation Plan at 2026 Investor Day

    Plan advances Bunge's ambition to become the premier agribusiness solutions company built for the 21st century Updates EPS mid-cycle baseline to ~$13 and provides growth for an expected increase to at least $15 by the end of 2030 Announces new $3 Billion Share Repurchase Program and commitment to returning a minimum of 50% of discretionary cash flow to shareholders through dividends and share repurchases across the cycle, underscoring confidence in long-term outlook Live webcast of Investor Day program begins at 9 a.m. EDT Bunge Global SA (NYSE:BG) will host its 2026 Investor Day, "Origins to Opportunities," today in New York at 9 a.m. EDT and via a concurrent webcast. The even

    3/10/26 8:00:00 AM ET
    $BG
    Packaged Foods
    Consumer Staples

    $BG
    $DICE
    $KDNY
    $QUOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bunge Limited

    SC 13G/A - Bunge Global SA (0001996862) (Subject)

    11/7/24 12:58:26 PM ET
    $BG
    Packaged Foods
    Consumer Staples

    Amendment: SEC Form SC 13G/A filed by Bunge Limited

    SC 13G/A - Bunge Global SA (0001996862) (Subject)

    11/6/24 2:13:04 PM ET
    $BG
    Packaged Foods
    Consumer Staples

    SEC Form SC 13G/A filed by Bunge Limited (Amendment)

    SC 13G/A - Bunge Global SA (0001996862) (Subject)

    3/7/24 12:29:51 PM ET
    $BG
    Packaged Foods
    Consumer Staples